April 19, 2026 Blog, Articles BPC-157, Category 2 Peptides, DN Lab Research, Epitalon, FDA Compounding, FDA Peptides, GHK-Cu, KPV, MOTS-C, PCAC, Peptide Reclassification, Peptide Regulation, Peptide Update 2026, Semax

Peptide Update 2026: FDA Removes 12 Peptides From Category 2 – Full Breakdown

A significant peptide update in 2026 has set in motion a significant regulatory shift for some of the most widely researched compounds in the peptide space. Following an announcement by Robert F. Kennedy Jr., United States Secretary of Health and Human Services, 12 peptides previously classified under FDA Category 2 will be removed from that

April 13, 2026 Articles, Blog BPC-157, CJC-1295, Epitalon, Growth Hormone Peptides, Peptide Cycle, Peptide Rebound, Peptide Therapy, Post-Cycle Recovery, Selank, Semax, Stopping Peptide Therapy

Stopping Peptide Therapy: What You Need To Know

There is no shortage of information about starting a peptide cycle. Protocols, dosing schedules, and expected benefits are well documented. What receives far less attention is the other end of the process. Stopping Peptide Therapy is a biological event in its own right, and for a meaningful proportion of people, the transition off a cycle

Tag: Semax

Peptide Update 2026: FDA Removes 12 Peptides From Category 2 – Full Breakdown

Stopping Peptide Therapy: What You Need To Know